SCHEMBL17326434

SCHEMBL17326434

COc1cccc(OC)c1-c1cc(C(=O)N[C@H](CC(=O)NC2CCC2)CC(C)C)nn1CC(C)C

nearest known ligand 0.80

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ APLNR P35414 20/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21229232 1.00 APLNR (0.80) APLNR
SCHEMBL17326321 0.98 APLNR (0.80) APLNR
SCHEMBL21229198 0.98 APLNR (0.80) APLNR
SCHEMBL21229187 0.97 APLNR (0.75) APLNR
SCHEMBL17326441 0.97 APLNR (0.75) APLNR
SCHEMBL17326436 0.94 APLNR (0.71) APLNR
SCHEMBL21468241 0.94 APLNR (0.71) APLNR
SCHEMBL17326438 0.94 APLNR (0.71) APLNR
SCHEMBL21468235 0.94 APLNR (0.71) APLNR
SCHEMBL17326312 0.92 APLNR (0.71) APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12629352-B2 Methods and uses for apelin receptor agonists RESEARCH TRIANGLE INSTITUTE (US) 2026-05-19 — — US claimed
US-20220280483-A1 METHODS AND USES FOR APELIN RECEPTOR AGONISTS RESEARCH TRIANGLE INSTITUTE 2022-09-08 — — US claimed
US-11401244-B2 Apelin receptor (APJ) agonists and uses thereof RESEARCH TRIANGLE INSTITUTE (US) 2022-08-02 — — US claimed
EP-4021447-A1 METHODS AND USES FOR APELIN RECEPTOR AGONISTS Research Triangle Institute (US) 2022-07-06 — — EP claimed
CN-106459004-B Apelin receptor (APJ) agonists and uses thereof 研究三角协会 2020-09-15 — — CN claimed
US-10377718-B2 Apelin receptor (APJ) agonists and uses thereof RESEARCH TRIANGLE INSTITUTE (US) 2019-08-13 — — US claimed
US-12629352-B2 Methods and uses for apelin receptor agonists RESEARCH TRIANGLE INSTITUTE (US) 2026-05-19 — — US disclosed
US-20220280483-A1 METHODS AND USES FOR APELIN RECEPTOR AGONISTS RESEARCH TRIANGLE INSTITUTE 2022-09-08 — — US disclosed
EP-4021447-A1 METHODS AND USES FOR APELIN RECEPTOR AGONISTS Research Triangle Institute (US) 2022-07-06 — — EP disclosed
US-20190315693-A1 APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF RES TRIANGLE INST (US) 2019-10-17 — — US disclosed
US-10377718-B2 Apelin receptor (APJ) agonists and uses thereof RESEARCH TRIANGLE INSTITUTE (US) 2019-08-13 — — US disclosed
US-20160207889-A1 APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF RESEARCH TRIANGLE INSTITUTE 2016-07-21 — — US disclosed
US-20160207889-A1 APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF RESEARCH TRIANGLE INSTITUTE 2016-07-21 — — US disclosed
WO-2015188073-A1 APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF RESEARCH TRIANGLE INSTITUTE (US) 2015-12-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12629352-B2 Methods and uses for apelin receptor agonists APLNR, CCR8, AP3B1 APLNR 1/4885
US-20160207889-A1 APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF APLNR, AP1G1, APMAP APLNR 1/4885
US-11401244-B2 Apelin receptor (APJ) agonists and uses thereof APLNR, AP1G1, APMAP APLNR 1/4885
US-20220280483-A1 METHODS AND USES FOR APELIN RECEPTOR AGONISTS APLNR, PLAUR, EDNRB APLNR 1/4885
US-10377718-B2 Apelin receptor (APJ) agonists and uses thereof APLNR, AP1G1, APMAP APLNR 1/4885
US-20190315693-A1 APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF APLNR, AP1G1, APMAP APLNR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback